Immunovant Inc

Immunovant Inc

IMVT

Get informed when a big investor buys or sells

+ Follow
Market Cap$6.94B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Immunovant IncImmunovant Inc-11.9--73%--
$4.94

Current Fair Value

85.3% downside

Overvalued by 85.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$6.94 Billion
Enterprise Value$6.14 Billion
Dividend Yield$- (-)
Earnings per Share$-2.77
Beta0.81
Outstanding Shares205,545,373

Return

Return on Equity-73.19%ROE
Return on Assets-63.13%
Return on Invested Capital-60.45%

Valuation & Multiples

P/E Ratio-11.92P/E Ratio
PEG-44.09PEG
Price to Sales-Price to Sales
Price to Book Ratio11.21Price to Book Ratio
Enterprise Value to Revenue865.6
Enterprise Value to EBIT-13.82
Enterprise Value to Net Income-12
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 12, 2026
EPS Estimate
$-0.60
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Next Earnings Call

Expected Date
November 9, 2026
EPS Estimate
$-0.73
Average shareholder expectation
Revenue Estimate
$7.09 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.1536▲ 4.90%
Total Calls1,801,100▼ 28.30%
Total Puts276,600▲ 5.25%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %54.04%▼ 0.27%
Total Invested$4.28B▲ 55.68%
Investors Holding240▲ 13.00%

ESG Score

No data

About Immunovant Inc